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Localization of overexpressed c-myc mRNA in polycystic kidneys of the
epic mouse. The C57BL/6J-cpk mouse has a form of autosomal-recessive
polycystic kidney disease characterized by the rapid growth of large
collecting duct cysts and the development of severe renal failure usually
by three to four weeks of age. Previous studies had shown higher
steady-state levels of proto-oncogene mRNA in these cystic kidneys. It
is now shown using nuclear run-on transcription that the c-fos and
c-myc proto-oncogenes are transcribed at higher rates in cystic kidneys,
and thus that increased transcription, in part, may account for the
increased mRNA levels. c-myc mRNA was detected by in situ hybrid-
ization in nephron anlagen and elongating tubules of normal and cystic
kidneys during late fetal and early neonatal kidney development.
Localization of c-myc expression in the normal kidney decreased with
age over the three-week postnatal period. By contrast, c-myc mRNA
was found in cysts as early as three days of age, with increased levels
at two and three weeks. c-myc expression was also elevated in
apparently normal, non-dividing proximal tubules in three-week-old
cystic animals. On the basis of these findings, we suggest that c-myc
expression is linked to the proliferation of cells engaged in the primary
cystogenic process, and that expression of this gene in proximal tubule
cells of severely azotemic animals reflects the compensatory response
of residual tubular epithelial cells to progressive renal dysfunction.
Polycystic kidney disease (PKD) in humans can be inherited
as an autosomal dominant [1] or autosomal recessive [2] trait, or
can be provoked by environmental factors (acquired cystic
disease) [3]. PKD is characterized by the growth of large
epithelial-lined cysts derived from the nephrons and collecting
ducts of affected kidneys [4J. Cysts are thought to initiate as
small dilations in renal tubules, which then expand into fluid-
filled cavities of relatively large size. In some cases, cyst
formation appears to involve both increased cell proliferation
and epithelial fluid secretion [5]. In addition, polycystic kidneys
also display changes in tubular basement membrane [6, 7],
tubular epithelial polarity [8], and growth factor expression [9].
Despite the growing list of morphological and biochemical
abnormalities that have been found in polycystic kidneys, the
pathogenesis of PKD which ultimately leads to kidney failure is
not yet understood.
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We are currently investigating the C57BLI6J-cpk mouse
which manifests PKD in a manner similar to human autosomal-
recessive polycystic kidney disease [10]. Autosomal-recessive
PKD is characterized by the rapid development of renal cysts,
primarily of collecting duct origin, and renal failure early in life
[2]. Cystic disease in the affected cpklcpk mouse begins with
dilations of proximal tubules in fetal and newborn animals. The
cortical and medullary collecting ducts start to enlarge shortly
after birth, and by three weeks of age the affected animals have
grossly distended abdomens due primarily to the expansion of
these collecting duct cysts. The cystic mice die of kidney
failure, usually during their fourth postnatal week.
Previous studies undertaken in our lab have shown marked
overexpression of the c-fos, c-myc, and c-Ki-ras proto-onco-
genes in cpk mouse kidneys [11—13]. The transient expression of
c-fos and c-myc is usually associated with increased mitogenic
activity, and when constitutively expressed or abnormally high
is characteristic of unregulated cell growth [14]. In the devel-
oping kidney, c-myc expression occurs in uninduced nephro-
genic mesenchyme and immature tubules, in association with
the increased cell proliferation seen at that time [15]. Thus, the
high levels of c-fos and c-myc mRNA in cystic kidneys may
indicate that certain cells in these kidneys are in a state of
persistent or unregulated mitogenic stimulation.
An examination of cell proliferation in the cystic kidneys of
cpk mice has indicated that rates of cell division are somewhat
elevated and that cell number increases about threefold over
normal during the three-week postnatal period [10, 11]. While
this increase in mitotic activity probably accounts for some of
the elevated c-fos and c-myc expression, it has been noted that
proto-oncogene expression increases out of proportion to the
expression of histone H4, which is a marker of cell proliferation
[10—131. These results suggested to us that proto-oncogene
expression may also occur in non-dividing cells and might be
associated with other processes involved in the pathogenesis of
polycystic kidney disease.
In order to understand the role of proto-oncogene overex-
pression in polycystic kidney disease, we have determined the
level of regulation at which c-fos and c-myc expression is
altered and in which kidney cells proto-oncogene expression is
affected. The results suggest that two different processes may
be responsible for elevated proto-oncogene expression in cystic
kidneys; one occurring early in the disease that is associated
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with increased cell proliferation and cystogenesis, and a second
occurring late in the disease that is associated with the com-
pensatory response to kidney failure.
Methods
Animals
CS7BL/6J-cpk mice were obtained from the Jackson Labora-
tory (Bar Harbor, Maine, USA), and have been maintained as a
breeding colony at the University of Kansas Medical Center.
Offspring of heterozygous breeders were examined at 16 gesta-
tional days, 3 postnatal days and at 1, 2, and 3 weeks of age.
Nuclear run-on transcription
Nuclei from the kidneys of three-week-old cpk/cpk polycystic
mice (N = 4) and phenotypically normal littermates (N 5)
were isolated by the method of Lamars, Hanson and Meisner
[16]. Run-on transcription analysis was carried out by modifi-
cation of methods used by others [16, 171. Briefly, 3 >< iO
normal and cystic kidney cell nuclei were suspended in 200 d of
transcription buffer (25% glycerol, 2.5 mrvi MgCI2, 0.05 mM
EDTA, 75 mi Hepes pH 7.5, 100 mi KC1, 4 m'vi DTT, 0.5 mM
CTP, 0.5 mivi GTP, 1 m ATP, 8.8 mi creatine phosphate, 0.04
mg/ml creatine kinase, 300 pCi of 800 Cilmmol [a-32P] UTP)
and then incubated at room temperature for 15 minutes. The
reactions were terminated by adding 260 d of DNase I incuba-
tion buffer (30 mivi Tris-HC1 pH 7.4, 15 m CaCI2, 90 g/ml
yeast tRNA) and 50 l of DNase 1/proteinase K solution (0.5
mg/mi DNase I, 0.5 mg/mi proteinase K, 20 mM Tris-HC1 pH
7.4, 10 mivi CaC12) that had been preincubated 30 minutes at
37°C. Digestion of nuclei was carried out at 37°C for 30 minutes
with frequent agitation. Seventy microliters of a solution con-
taining 0.5 mM EDTA and 10% SDS were added and incubation
continued for 15 minutes. Extraction was carried out with
phenol/chloroform. The RNA was then precipitated by adding
an equal volume of 20% TCA and incubating on ice. Unincor-
porated 32P-UTP was removed from the pellet by multiple
washings with 5% TCA. The RNA pellet was dissolved and
then ethanol precipitated. The labeled RNA was redissolved in
HENS/tRNA (20 mi Hepes pH 7.0,5 mrvi EDTA, 50 mivi NaC1,
0.1% SDS, 1 mg/mi yeast tRNA) and incorporation of radioac-
tivity was measured by scintillation counting.
Nitroceilulose filters were slot-blotted with 1 g each of
linearized plasmids containing a c-fos, c-myc, hsp7O and
preproEGF DNAs. After baking, the filters were prehybridized
and hybridized in the manner used for Northern blots [18] with
1 x iO cpm of transcribed RNA. Washing was carried out at
65°C for several hours in 5x SSC (SSC is 0.15 M NaC1, 0.015 M
Na3citrate, pH 7), 0.1% SDS, then for several more hours in 2x
SSC, 0.1% SDS. The filters were autoradiographed and the
relative intensity of the hybridization signal was determined by
densitometry.
Cycloheximide treatment
Cycloheximide treatment was used in some animals to stabi-
lize mRNAs to increase the sensitivity of in situ hybridization.
Mice were injected intraperitonealiy with 0.01 ml/g (body
weight) of 5 mg/mi cycloheximide solution (dose = 50 g/g body
weight) made in 150 m sodium bicarbonate, pH 8. Untreated
controls were injected with the same volume of bicarbonate
buffer.
In situ hybridization
The methods for in situ hybridization are described in Hard-
ing et al [19]. Briefly, mice were anesthetized with sodium
pentobarbitai and their kidneys were fixed by perfusion with 4%
paraformaldehyde in phosphate-buffered saline (PBS) followed
by immersion in the same fixative. Pieces of kidney were
cryoprotected by soaking in 15% sucrose/PBS then embedded
in ornithine carbamyl transferase (OCT) compound and snap-
frozen in liquid N2. Eight micrometer sections were mounted on
poly-L-lysine coated slides and fixed an additional 15 minutes in
4% paraformaldehyde/PBS. After rinsing in PBS, slides were
acetyiated, washed in 2x SSC, and dehydrated in ethanol.
Sections were incubated first in 5 mi MgCl2/PBS and then in
0.25 M Tris, 0.1 NI glycine, pH 7. A wash of 50% formamide, 2 x
SET (SET is 0.15 M NaCl, 2 mM EDTA, 0.03 M Tris, pH 8) was
carried out at 37°C for 10 minutes. Hybridization solution,
containing 2x SET, lOx Denhardt's solution, 250 mg/mi yeast
tRNA, 50% formamide, 0.1 M DTT, 10% dextran sulfate, and
approximately 0.05 g/ml of 35S-labeled cRNA probe was
placed on the sections, then covered with a siliconized cover-
slip and immersed in paraffin oil. Hybridization took place
overnight at 45°C. Excess paraffin oil was removed by washing
in CHC13, and coverslips were removed by soaking in 4x SSC.
Slides were washed in 50% formamide, 2x SET, 10 mrvi DTT
for 15 minutes at 60°C, then incubated with RNase A (20 .tg/ml
RNase A, 3x SET, 100 JLg/ml BSA) for 30 minutes at 37°C.
After washing in 1 x SSC at room temperature, the slides were
washed a final time in 0.2x SSC, 0.1% mercaptoethanol at 50°C
for 30 minutes, then dehydrated in ethanol. Autoradiography
was performed with Kodak NTB-2 liquid emulsion. The sec-
tions were stained in hematoxylin and eosin following develop-
ment.
DNA probes
The c-myc, c-fos, hsp7o and preproEGF subciones were
supplied by Dr. G. Andrews. The c-fos clone consists of a 1.8
kb EcoRI/SstI fragment of a mouse clone from American Type
Culture Collection subcloned into pSP64. This subclone spans
the last three exons of the c-fos gene and was linearized with
EcoRI prior to transcription. The c-myc clone consists of a 1.9
kb Hindill/Saci insert from a mouse c-myc clone obtained from
the American Type Culture Collection. The insert was direc-
tionally cloned into pSP64 and when linearized with PvuII and
transcribed, yields a 500-base cRNA probe containing exon 3
sequences. The c-fos and c-myc subclones do not contain exon
1 sequences, where termination of transcriptional elongation is
thought to occur.
A mouse hsp7o clone was obtained from Dr. Richard Mori-
moto. The subclone consists of a 1.9 kb BamHI/EcoRI coding
region fragment inserted into pSP64. This clone when linearized
with XmnI yields a 990 base cRNA probe. The preproEGF
clone has been previously described [9].
Results
Our previous studies showed approximately tenfold and
30-fold increases, respectively, in c-fos and c-myc steady state
mRNA levels in cystic kidneys [11—131. These elevated mRNA
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Fig. 1. Nuclear run-on transcription analysis. 32P-labeled run-on tran-
scripts synthesized in normal (NL) and cystic (CY) kidney cell nuclei
from 3-week-old mice hybridized to cloned c-fos, c-myc, hsp7O, pre-
proEGF (EGF), and pGEM (Promega) plasmid vector DNAs slot-
blotted and immobilized on nitrocellulose.
levels could be due either to increased gene transcription or to
post-transcriptional mechanisms such as increased mRNA sta-
bility. To determine if increased rates of gene transcription are
responsible for the increased mRNA levels, nuclear run-on
transcription studies were carried out using nuclei isolated from
three-week-old cystic and normal mouse kidneys (Fig. 1). This
analysis showed that the c-fos and c-rnyc genes are transcribed,
respectively, at 6.3-fold and 2.3-fold higher rates in cystic as
compared to normal kidneys. In contrast, the hsp7O and pre-
proEGF genes, which are transcribed at relatively low levels in
normal kidneys, demonstrated no increase in cystic kidneys.
This latter result is consistent with Northern blot evidence
which showed that hsp70 mRNA is not significantly increased
(Harding and Calvet, unpublished results) and that preproEGF
mRNA levels are actually lower in cystic kidneys [9J. These
results, therefore, show that some of the increased c-fos and
c-rn ye mRNA may be accounted for by increased rates of gene
transcription.
The protein synthesis inhibitor cycloheximide has been found
to increase the amounts of c-fos and c-rnyc mRNA in cells
expressing these genes [20—26]. Because of the increased tran-
scriptional activity of these genes in cystic kidneys, we rea-
soned that cycloheximide might superinduce c-fos and c-myc
mRNA. Previous studies by others indicated that c-myc expres-
sion can be superinduced in vivo in rat liver after partial
hepatectomy [27]. Thus, we sought to amplify the difference in
c-fos and c-myc mRNA levels seen between normal and cystic
kidneys (Fig. 2A, lanes I and 4) by pretreating mice with
cycloheximide. One hour after injection, the mice were sacri-
ficed and total kidney RNA was isolated. Northern blot analysis
demonstrated that cycloheximide treatment amplified the c-fos
and c-rnyc mRNA steady-state levels in both normal and cystic
kidneys (Fig. 2A, lanes 2 and 5), giving rise to much more c-fos
and c-myc mRNA in the cystic kidneys than in the normals.
This effect of cycloheximide treatment on c-fos and c-rn ye
Fig. 2. Induction of c-fos and c-myc ,nRNAs by cycloheximide treat-
ment. Northern blot analysis of c-fos and c-myc mRNAs carried out
with total kidney RNA from 3-week-old normal and polycystic mice.
(A) RNA isolated after a 1-hour treatment, from normal mice injected
with carrier NaHCO3 (lane I) or cycloheximide (lane 2), from unin-
jected cystic mice (lane 3), or from cystic mice injected with carrier
NaHCO3 (lane 4) or cycloheximide (lane 5). (B) RNA isolated after a
3-hour treatment, from normal mice injected with carrier NaHCO3 (lane
1) or cycloheximide (lane 2), or from cystic mice injected with carrier
NaHCO3 (lane 3) or cycloheximide (lane 4).
mRNA lasted several hours, since the amplified levels of these
two mRNAs were also found three hours after injection (Fig.
2B). These results establish that cycloheximide can be used to
augment the differential expression of c-fos and c-rnyc mRNAs
in normal and cystic kidneys.
The kidney is a heterogeneous organ with a complex tubular
architecture composed of many different cell types. Some
tubular segments are profoundly altered in cystic kidneys while
others appear essentially normal. While c-rnyc mRNA was
found to be elevated in cystic kidneys at all stages examined,
most of the increased expression was seen between two and
three weeks, when the rate of cell proliferation is actually
decreasing 110, 11, 13]. Therefore, an understanding of the role
that the elevated c-rnyc expression may play in PKD depends
upon a knowledge of which cell types account for this abnormal
expression. To localize the increased c-rnyc expression in cystic
kidneys, in situ hybridization was carried out using perfusion-
fixed, frozen sections hybridized with an 35S-labeled anti-sense
RNA probe. As a control, sections of small intestine were
hybridized alongside kidney sections. The intestinal epithelium
is continually regenerating, with cell proliferation occurring at
the base of the villi in the crypts of Lieberkuhn [28]. Therefore,
it would be expected that most c-rnyc expression in the gut
would be localized to the small population of proliferating cells
in these crypts. Indeed, in situ hybridization with the c-rnyc
probe demonstrated significant labeling of the crypts (Fig. 3A),
indicating that the technique is quite specific. In some experi-
ments, cycloheximide was used to increase the sensitivity of in
situ hybridization. As shown in Figure 3B, cycloheximide
pretreatment did not alter the pattern of c-rnyc expression in the
gut, suggesting that it did not induce expression in cells not
already expressing c-rn ye.
In both normal and cystic kidneys at 16 days in utero and
three postnatal days of age, c-myc mRNA was localized pri-
marily in the nephrogenic zone of the outer cortex (Fig. 4, A-D,
arrows). While label could also be seen in cystic epithelium
(Fig. 4D, arrowheads), most of the c-rnyc mRNA at these early
time points appeared to be associated with normal developmen-
tal expression. At one week, labeling associated with the outer
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Fig. 3. Localization of c-myc mRNA in intestinal ctypts. In situ hybridization bright and dark field photomicrographs of 3-week-old (A) untreated
and (B) 3-hour cycloheximide-treated mice. Bar = 100 jzm.
Fig. 4. Localization of c-myc mRNA in nephrogenic kidneys. In situ hybridization bright and dark field photomicrographs of nephrogenic vesicles
(arrows) in (A) normal and (B) cystic kidneys at 16 gestational days, and in (C) normal and (D) cystic kidneys at 3 postnatal days. Labeled cysts(arrowheads) can be seen at 3 days. Bar = 200 m.
cortex was seen to decline as the number of newly developing probe appeared to hybridize to the outer medulla in association
nephrons decreased, but was apparent in the medullary rays with newly developing collecting duct cysts (Fig. 5B, arrow-
(Fig. 5A, B, small arrows). In the one-week cystic kidney, more heads), with less labeling occurring near the tip of the papilla
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Fig. 5. Localization of c-myc mRNA in maturing normal and cystic kidneys. In situ hybridization bright and dark field photomicrographs of
1-week (A) normal and (B) cystic kidneys showing medullary rays (small arrows), labeled cysts (arrowheads), and the tip of the renal papilla (large
arrow), and 2-week (C) normal and (D) cystic kidneys showing collecting duct cystic epithelium (arrows). (A,B) Bar = 200 tm; (C,D) Bar = 100
m.
(Fig. 5B, large arrow). At two weeks of age, the normal kidney
contained much less c-myc mRNA (Fig. 5C). However, the
cystic kidney had generally higher levels of c-myc expression,
in particular in the epithelial lining of collecting duct cysts (Fig.
5D, arrows). It is important to note that specific localization of
c-myc mRNA to tubule segments comprising normal-appearing
nephrons was not seen in two-week cystic kidneys. At three
weeks, the difference in c-myc expression between normal and
cystic kidneys was quite pronounced. Very little c-myc mRNA
was detected in the normal kidney (Fig. 6A), and high levels of
c-myc mRNA were detected in the cystic kidney (Fig. 6B-D).
Labeling of the cystic epithelium was somewhat heterogeneous,
with some cysts showing more hybridization than others (Fig.
6C, arrows), and with some regions within single cysts having
more hybridization than other regions. Surprisingly, in addition
to the cystic epithelium, a large amount of the c-myc probe
hybridized to normal-appearing proximal tubules in the cystic
kidney (Fig. 6B, D, arrows). Such a large concentration of
c-myc mRNA in the proximal tubules was unexpected, since
there were no indications of increased rates of cell proliferation
in these proximal tubules in the same tissue sections used in this
study or in previous studies that specifically addressed this
issue in the three-week cpk mouse kidney [10]. Thus, both the
cyst wall epithelium and proximal tubules seem to contribute to
the overexpression of c-myc mRNA detected in whole kidney
RNA by Northern blot hybridization.
To increase the sensitivity of in situ hybridization, three-
week-old mice were pretreated with cycloheximide. As noted
above, cycloheximide did not alter the pattern of c-myc hybrid-
ization in the intestines of normal mice (Fig. 3B). In normal
kidneys, cycloheximide treatment allowed the detection of
c-myc mRNA in proximal tubules (Fig. 6E, arrow); however,
no labeling was observed in collecting ducts anywhere in the
kidney, this being particularly evident in the medulla (Fig. 6E,
bottom). The lack of c-myc expression in normal collecting
ducts even after cycloheximide enhancement is significant
because it demonstrates that any c-myc expression detected in
these cells in cystic kidneys is clearly abnormal. In cystic
kidneys, the level of c-myc mRNA in the cyst wall epithelium
(small arrow) and proximal tubules (large arrow) was greatly
amplified by cycloheximide treatment (Fig. 6F). The increased
levels of c-myc mRNA made it possible to detect some level of
expression in almost all of the collecting duct cysts, confirming
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Fig. 6. Localization of c-myc mRNA in 3-week-old normal and cystic kidneys. In situ hybridization bright and dark field photomicrographs
showing (A) normal and (B) cystic kidneys under low power magnification demonstrating proximal tubule labeling (arrow), (C,D) cystic kidneys
under higher magnification demonstrating (C) the variability of cyst labeling (arrows) and (D) proximal tubule labeling (arrows), and (E) normal and
(F) cystic kidneys 3 hours after cycloheximide treatment showing (E) a normal kidney with labeled proximal tubules (arrow) throughout the cortex,
and (F) a cystic kidney with labeled cysts (small arrow) and proximal tubules (large arrow). (A,B,E,F) Bar = 100 m; (C,D) Bar = 40 sm.
that the majority of cells lining cysts abnormally express c-myc [11—131. We have now found that the c-fos and c-,nyc genes are
mRNA. transcribed at higher rates in cystic compared to normal kid-
neys. This difference in transcription rates may account, in
Discussion part, for the elevation of c-fos and c-myc mRNAs in cystic
Previous studies had shown that several proto-oncogene kidneys. Transcription rates of the c-fos and c-myc genes
mRNAs are markedly elevated in the cystic kidneys of cpk mice appear to be selectively elevated, since the transcription of two
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other genes was not increased. This would suggest that the cpk
mutation directly or indirectly affects signal transduction mech-
anisms responsible for the transcriptional regulation of the c-fos
and c-myc genes.
The rates of transcription of the c-fos and c-myc genes were
found to be elevated in cystic kidneys approximately 6.3-fold
and 2.3-fold, respectively. It should be noted that the steady
state c-fos and c-myc mRNA levels were found previously to be
elevated about tenfold and up to 30-fold, respectively [11—131.
For c-myc, therefore, it appears that there is only a relatively
modest increase in transcription rate compared to the large
increase in mRNA amount in cystic kidneys. This would
suggest that there is also a significant post-transcriptional
component to the regulation of c-myc gene expression in cystic
kidneys. Indeed, it has been reported by Asselin and Marcu [29]
that post-transcriptional mechanisms are largely responsible for
the marked induction of c-myc mRNA levels in regenerating
mouse kidneys following folic acid-induced injury [18], and in
contrast that c-fos is regulated primarily at the transcriptional
level in these kidneys [29].
We have shown that the elevation in c-fos and c-myc mRNAs
in cpk mouse kidneys can be greatly amplified by treatment with
the protein synthesis inhibitor cycloheximide. Although cyclo-
heximide treatment also raised the level of these mRNAs in the
kidneys of phenotypically normal littermates, this increase was
not nearly as dramatic as that seen in cystic kidneys. Cyclo-
heximide is known to cause superinduction of a number of
proto-oncogene and growth factor mRNAs due both to in-
creased gene transcription and to increased mRNA half-life
[20—26, 30—32]. It is important to note, however, that cyclohex-
imide by itself probably does not induce increases in c-fos and
c-myc mRNA levels in quiescent cells not previously express-
ing these two genes [21, 22, 25]. Based on the cycloheximide
results, therefore, it would seem that the c-fos and c-myc genes
are probably under a state of increased or continuous transcrip-
tional stimulation in the cystic kidney, in agreement with the
nuclear run-on results.
Previous studies had indicated that abnormal cell prolifera-
tion occurs in the cystic kidneys of cpk mice [11, 13]. It had also
been shown that c-myc mRNA levels are elevated in cystic
kidneys even at early stages of cyst development. Therefore,
the elevation in c-myc expression may be a reflection of this
abnormal cell proliferation, and the localization of c-myc over-
expression in the cyst wall epithelium can be attributed to the
increased cell proliferation necessary for cyst formation. Since
some cysts had much higher levels of c-myc mRNA than others,
it is possible that epithelial proliferation rates vary between
cysts. Cysts are heterogeneous in size, which may be the result
of different growth rates or of variability in the onset of the
initiation and/or termination of cyst growth. This variation in
cyst growth could be linked to epigenetic factors.
Recent evidence obtained from studies using transgenic mice
which express the SV4O large T antigen [33, 34] or c-myc [35,
36] genes suggests that proto-oncogene overexpression may
initiate cyst formation. Transgenic mice expressing a c-myc
gene driven by an SV4O enhancer developed polycystic kid-
neys, with a predominance of cysts arising from collecting
tubules [35, 36]. In these studies, in situ hybridization revealed
that high levels of c-myc mRNA were localized in the cyst wall
epithelium. Similar experiments with the SV4O enhancer and
large T antigen gene resulted in transgenic animals that devel-
oped tubular cysts [36]. The SV4O enhancer may play a role in
the temporal and tissue specific expression of these transgenes
and could be critical for development of renal cysts in these
transgenic animals [37—39]. These transgenic studies support
the idea that the elevated c-myc expression observed in the cpk
mouse kidney may be directly involved in the pathogenesis of
PKD. In the cpk mouse, however, it is likely that the primary
defect is in a gene that, when abnormally expressed, leads to
the misregulation of a number of genes including c-myc.
Cell proliferation and proto-oncogene expression are fre-
quently associated with early development. c-myc expression
has been found in several tissue types in developing mouse [40,
41] and human [42] embryos. In the kidney, c-myc expression is
highest in the early fetus (fetal day 12) and decreases during
tubule differentiation from fetal day 12 through newborn [15].
We have also seen a decline in c-myc expression in the
developing kidney, which we have examined from fetal day 16
through three weeks of postnatal development [13] (Figs. 4—6).
Of particular significance is the observation that very little, if
any, c-myc expression can be detected in collecting ducts at any
developmental stage [15] (Figs. 4—6).
The increased cell proliferation and c-myc expression in
cystic kidneys may be an indication that cyst wall cells are not
fully differentiated. Constitutive proto-oncogene expression is
frequently associated with a less-differentiated state [43, 44]. In
particular, expression of the c-myc gene has been shown to
block differentiation of mouse erythroleukemia cells [45], F9
teratocarcinoma cells [46], pre-B-cells [47], and rat myoblasts
[48]. Furthermore, expression of the retroviral v-myc oncogene
in avian sympathetic neurons maintains the cells in an imma-
ture, proliferating state [49]. It is possible, therefore, that the
cpk mutation working through c-myc and perhaps other genes
interferes with normal kidney development and differentiation.
Indeed, other lines of evidence are consistent with the idea that
cystic kidneys have a developmental abnormality. The pre-
proEGF gene, which is normally expressed at high levels in
distal tubules starting at one week and increasing through three
weeks of age, has been found to be significantly underexpressed
in cystic kidneys [9]. This lack of EGF expression may be a
result of abnormal distal tubule development. We have also
discovered that the sulfated glycoprotein-2 (SGP-2) gene is
persistently expressed in collecting duct cysts, where in normal
kidneys it is developmentally down-regulated, suggesting that
cyst epithelial cells are not terminally differentiated [19]. Fur-
thermore, the polarity of cyst epithelial cells has been found to
be reversed with respect to Na-K ATPase, a characteristic of
immature, relatively undifferentiated collecting duct epithelium
[8]. Thus, it appears that cyst epithelial cells, as a consequence
of the abnormal gene expression associated with the cpk
mutation, do not differentiate normally.
Our finding that c-myc mRNA is expressed at elevated levels
in proximal tubules of three-week cystic kidneys was surprising
since previous work revealed no evidence for proliferation of
these cells [10]. The c-los and c-myc proto-oncogene products
are thought to play a role in the transition from G through the
G1 phase of the cell cycle. However, there is also evidence that
c-myc can be disassociated from cell division. It has been
shown, for example, that c-myc expression is high in Xenopus
oocytes, which are not dividing, and that it does not increase
324 Harding et at: Overexpressed c-myc in cpk mouse kidneys
during the subsequent cleavage stage in which there is rapid cell
division [50, 51]. Thus, it was found in those studies that there
was no correlation between the onset of DNA synthesis and
c-myc expression [51]. Furthermore, during development of the
human embryo, some rapidly growing tissues express c-myc
mRNA while others express very little [42]. These observa-
tions, and our own, emphasize that caution must be used in the
interpretation of c-myc expression as a simple marker for
mitotic activity.
As noted earlier, the first detectable changes in the cpk mouse
kidney are in the proximal tubules. However, these changes are
not a prominent feature of the latter stages of the disease
process, and at three weeks of age morphologically normal
proximal tubules are present, although in reduced number. At
three weeks, the elevated c-myc expression in proximal tubules
may represent a secondary effect of kidney failure. Acute renal
injury is known to elicit a compensatory response accompanied
by cell proliferation [18, 52—54]. A related process may occur in
cystic kidneys, where a loss of normal renal function might lead
to an attempt to increase proximal tubule mass. However, the
absence of cell division in these proximal tubules would indi-
cate that this compensatory, regenerative process cannot prog-
ress to the proliferative stage, and the elevated c-myc expres-
sion would suggest that these cells are blocked in G1, caused
perhaps by their inability to produce enough G1-specific cell
cycle proteins to proceed into S phase.
In conclusion, our results establish that the elevated c-myc
expression in the cystic kidneys of cpk mice is associated with
the cyst wall epithelium and thus that it is probably associated
with the increased rate of proliferation of this cell population.
While c-myc mRNA levels are elevated in cystic kidneys during
the first two postnatal weeks, this increase is not dramatic until
three weeks of age. This may be an indication that polycystic
kidney disease progresses in two stages in the cpk mouse [13].
In the first stage, the elevated (relatively low, but above-
threshold) c-myc expression may lock tubule cells in a less-
differentiated state, leading to the initiation of cyst formation
and the expansion of this population of cells, resulting in cyst
growth. In the second stage, the high c-myc expression in
non-proliferating proximal tubules may be a consequence of
secondary abnormalities resulting from formation of the very
large collecting duct cysts and the associated renal failure.
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